Genital herpes simplex infections: Some therapeutic dilemmas

Sexually Transmitted Diseases

Volumn 30, Issue 3, 2003, Pages 232-233

  Mills, John ^a   Mindel, Adrian ^b  

^a MONASH UNIVERSITY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; VALACICLOVIR; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; COST BENEFIT ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; GENITAL HERPES; HEALTH CARE COST; HERPES; HUMAN; LIFESTYLE; MORBIDITY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRACTICE GUIDELINE; QUALITY OF LIFE; RECURRENT DISEASE; SCORING SYSTEM; SIDE EFFECT; VIRUS SHEDDING; VIRUS TRANSMISSION; DRUG ADMINISTRATION; PATHOLOGY;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; HERPES GENITALIS; HUMANS; RECURRENCE;

EID: 0037334698     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200303000-00011     Document Type: Editorial

References (15)

1. Romanowski B, Valtrex HS230017 Study Group, Marina RB, Roberts JN. Patient preference of valacyclovir once daily suppressive therapy versus twice daily episodic therapy for recurrent genital herpes: a randomized study. Sex Transm Dis 2003; 30:xxx-xxx.
2. Patel R, Bodsworth NJ, Woolley P, et al. Valacyclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valacyclovir HSV Study Group. Genitourin Med 1997; 73:105-109.
3. Reitano M, Tyring S, Lang W, et al. Valacyclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valacyclovir HSV Study Group. J Infect Dis 1998; 178:603-610.
4. Mindel A, Faherty A, Carney O, Patou G, Freris M, Williams P. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet 1988; 1:926-8.
5. Mindel A. Psychological and psychosexual implications of herpes simplex virus infections. Scand J Infect Dis Suppl 1996; 100:27-32.
6. Carney O, Ross E, Ikkos G, Mindel A. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993; 69:457-459.
7. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K. A large-scale, placebo-controlled, dose-ranging trial of peroral valacyclovir for episodic treatment of recurrent herpes genitalis. Valacyclovir HSV Study Group. Arch Intern Med 1996; 156:1729-1735.
8. Sacks SL, Aoki FY, Diaz-Mitoma F, Sellors J, Shafran SD. Patientinitiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. Canadian Famciclovir Study Group. JAMA 1996; 276:44-49.
9. Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: a multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. Arch Intern Med 1997; 157:343-349.
10. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J 2002; 95:68-71.
11. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9:2-6.
12. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immun Defic Syndr 2001; 28:445-449.
13. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triplecombination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-1058.
14. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis 2002; 34:944-948.
15. Corey L, Tyring S, Beutner K, et al. Once daily valacyclovir reduces transmission of genital herpes [abstract LB-3]. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, California. September 27-30, 2002.